Stiris Research Inc. announces favourable FDA response on US pancreatic cancer program

London, ON — December 18, 2018 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce that the Australian biotech they are collaborating with on a pancreatic cancer program received a favourable FDA response following review of safety data compiled for research being done in the US, EU and Australia. The company has decided to close recruitment on the US trial based on this information and the fact that all obligations had been achieved.

“Stiris is excited to continue to work on this project and follow the ongoing subjects in the trial, as well as see the final outcomes of this trial. We always feel so fortunate to be involved in these trials and of course look forward to positive results for patients moving forward,” said Amanda Carrera, Vice President. “Stiris understands the beneficial impact these types of decisions from the FDA or other regulatory agencies have on companies, and that achieving these important milestones allow the company to further discuss moving their products forward.”

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.